USPTO Patent Applications - Biotech (C12N)

Nucleic Acid Complexes with Cationic/Anionic Polymers and RNA Molecules

The USPTO published patent application US20260096998A1 for nucleic acid complexes comprising cationic polymers, anionic polymers, and monomeric RNA molecules. The disclosed complexes feature a core structure where the cationic polymer and RNA molecule are encapsulated by the anionic polymer. The application covers linear and non-linear configurations of these complexes for therapeutic uses.

Microbial Compositions and Methods for Fermented Foods

USPTO published patent application US20260096563A1 for microbial compositions comprising purified populations of microorganisms used in producing dough or baked food products. The compositions are designed to enhance fermentation by improving rheological properties, nutritional quality, and shelf-life of dough and baked food products. The application was filed on December 9, 2025, with inventors Cameron Martino and James Gaffney.

Thraustochytrids, Fatty Acid Compositions, and Methods - DSM Assets

USPTO published patent application US20260096578A1 by DSM IP Assets B.V. covering isolated thraustochytrid microorganisms, microbial oils, biomasses, compositions, and associated production and use methods. The application, filed August 13, 2025, lists six inventors and covers CPC classifications spanning food, cosmetic, and pharmaceutical applications.

Controlled Movement Method for Gametes, Zygotes, Embryos

USPTO published patent application US20260098250A1 assigned to CIC nanoGUNE, filed September 6, 2023, covering a method and device for controlled movement of gametes, zygotes, and embryos using micro-scale carriers. The device comprises biocompatible carriers with maximum 500 μm dimensions that can releasably connect to biological cells and move autonomously or via external influences. The technology aims to enable less invasive procedures and higher implantation rates in reproductive medicine and healthcare applications.

G47ΔhIL12A Oncolytic HSV for Glioblastoma and Triple-Negative Breast Cancer Treatment

USPTO published patent application US20260097135A1 for G47ΔhIL12A, an oncolytic herpes simplex virus (oHSV) engineered with human IL-12 transgene driven by HCMV IE enhancer/promoter. The invention addresses augmented transgene production and increased virus replication while maintaining safety profiles. Applications include treatment of glioblastoma (GBM) and triple-negative breast cancer (TNBC). Filing date: September 26, 2023; Application No. 19114912.

Biallelic CIITA Knockout Patent, 34199 RNA Sequences

USPTO published patent application US20260097123A1 for compositions and methods for biallelic CIITA knockout using RNA molecules comprising guide sequences of 17-50 nucleotides. The application covers 34,199 sequences (SEQ ID NOs 1-34199). Inventor: Rafi Emmanuel. Filing date: September 19, 2023.

Biallelic Knockout CISH Gene, RNA Compositions

USPTO published patent application US20260097121A1 by inventor Rafi Emmanuel covering RNA compositions with guide sequences targeting the CISH gene for biallelic knockout. The application includes sequences defined by SEQ ID NOs 1-6838 and methods for their use. Filing date was September 18, 2023, under application number 19113098.

Phio Pharmaceuticals T Cell Induction Method for Cancer Treatment

USPTO published patent application US20260097120A1 assigned to Phio Pharmaceuticals Corp. The application covers methods for producing immunogenic compositions using ex vivo T cell treatment with oligonucleotide agents capable of controlling T cell differentiation through PD-1 silencing via chemically modified double-stranded nucleic acid molecules. The disclosed compositions and methods target cancer treatment, including melanoma.

Patent for RSV vaccine using F protein trimer prefusion conformation

Patent for RSV vaccine using F protein trimer prefusion conformation

Solid-State Storage of Biochemical Systems Patent Application

USPTO published patent application US20260098247A1 by inventor Javin Oza disclosing compositions and methods for solid-state storage of biological systems using polymeric cryoprotectants, saccharide cryoprotectants, emulsifiers, and lubricating flow agents, enabling cold chain-free, point-of-care platforms for diagnostics, research, biomanufacturing, and testing.

Ureteric Bud Kidney Tissue Engineering Compositions and Methods

The USPTO published patent application US20260098246A1 disclosing engineered ureteric bud kidney tissues and methods for making lumenized kidney tissues with spatially-controlled 3D tubular architecture. The application includes in vitro kidneys comprising nephron progenitor cells and ureteric bud cells. Inventors: Benjamin Shepherd, Alice Chen, J. William Higgins, III. Filed July 30, 2025.

Methods for Producing Highly Purified (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate for Enhancing Bodily Function and Treating Disease States

USPTO published patent application US20260098281A1 by Romeo Tango, LLC for methods of producing highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and biomedical uses thereof. The application covers therapeutic applications including inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additional applications include improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection.

Lipid-Encapsulated Dual-Cleaving Endonuclease for DNA and Gene Editing

USPTO published patent application US20260098248A1 for a lipid-encapsulated dual-cleaving endonuclease enabling non-viral gene editing methods, filed October 10, 2025 under application number 19355897. Inventors include David R. Edgell, Thomas A. McMurrough, Brent E. Stead, and Odisho K. Israel. The invention covers methods of administering a chimeric nuclease to cells or organisms without viral vectors.

Stem Cell Differentiation Method for Progenitor Cells and Organoids

The USPTO published patent application US20260098245A1 assigned to Koninklijke Nederlandse Akademie Van Wetenschappen (Royal Netherlands Academy of Arts and Sciences). The application, filed December 10, 2025, covers differentiation methods for progenitor cells including mammalian epithelial stem cells, differentiation media compositions for use in said methods, organoids and cells obtainable by said methods, and therapeutic uses thereof. Inventors are Johannes Carolus Clevers and Helmuth Gehart.

Harvard Patent - Automated Parallel Chromatography for Extracellular Vesicle Purification

USPTO published patent application US20260098244A1 from President and Fellows of Harvard College disclosing devices and methods for automated parallel chromatography for purification of extracellular vesicles from biological samples. The invention includes a pump, computing device, and a stand with columns containing resin and bottom wells or tubes. CPC classifications indicate applications in cell/vesicle technology and chromatography methods.

Dura Mater-Derived Stem Cells and Method for Producing the Same

USPTO published patent application US20260098243A1 for dura mater-derived stem cells and production methods. Inventors: Sun Hwa PARK, Sung Won KIM, Seung Ho YANG, Jung Eun LEE, Hyun Ji LEE. The application, filed 2025-10-06 under Application No. 19350367, covers methods of isolating stem cells from dura mater with serum supplements and their use in cell therapeutic agents.

Ultra-High Molecular Weight Xanthan Gum Engineered Strain and Detection Marker

The USPTO published patent application US20260098104A1 for an engineered bacterial strain that produces ultra-high molecular weight xanthan gum with molecular weight exceeding 2.0×10^7 Da, significantly above the ordinary range of 0.2×10^7-2.0×10^7 Da. The application also discloses a molecular marker for detecting the engineered strain and its processed products, enabling rapid identification in production and quality control contexts.

Novozymes A/S Patent for Enzymatic Plant Protein Extract Method

USPTO published patent application US20260096575A1 assigned to Novozymes A/S for an enzymatic method of producing plant protein extract. The method involves treating plant protein raw materials under alkaline conditions with protein deamidase added before, during, or after treatment, followed by protein recovery and spray drying. The resulting plant protein extract has improved solubility suitable for food or beverage applications. The application was filed on September 28, 2023.

In Vitro Bioproduction of Polyhydroxyalkanoate Monomers

USPTO published patent application US20260098283A1 by inventor Stephen Quirk for an enzymatic process to produce homogeneous chain length polyhydroxyalkanoate (PHA) monomers and polymers with chain lengths of at least eight carbons from long-chain fatty acids. The process enables specific, controlled production of PHA materials through in vitro enzyme contact with long-chain fatty acid precursors.

CO2 Conversion to C2+ Chemicals via Electrochemical and Microbial Process

USPTO published patent application US20260098282A1 disclosing a method for converting carbon dioxide to higher value C2+ chemicals using an electrochemical cell with a carbon dioxide reducing catalyst combined with microbial conversion. The application was filed on September 23, 2023, by inventors Peng Zhang, Kainan Chen, Joshua Shuhua Yuan, and Susie Y. Dai. The publication makes the application publicly available but does not constitute a granted patent.

BEST1 Vectors for Retinal Dystrophy Treatment

The USPTO published patent application US20260098277A1 covering BEST1-targeted expression constructs, nucleic acid vectors, and pharmaceutical compositions for treating BEST1-associated retinal dystrophies including autosomal dominant bestrophinopathies. The application includes BEST1-targeted shRNAs, BEST1 coding sequences, promoters, and regulatory elements designed to improve functional BEST1 expression in subjects with BEST1 mutations. This published application represents an early-stage intellectual property filing with no granted rights or compliance obligations established.

Methods of Improving Unique Molecular Index Ligation Efficiency

Illumina, Inc. has filed a patent application (US20260098256A1) for methods and adapter pools that improve unique molecular index (UMI) ligation efficiency in nucleic acid sequencing applications. The invention enables more accurate quantification of polynucleotide fragments by providing UMIs that are uniquely associable with individual fragments. The application was published April 9, 2026, with a filing date of December 12, 2025. Biotechnology companies developing next-generation sequencing technologies may need to review this application to assess potential impacts on their IP strategies or freedom-to-operate analysis. Researchers and diagnostic developers using UMI-based sequencing methods should monitor this and related patent activity for potential licensing implications.

Lysis Vessel with Dual Membranes and Non-Magnetic Beads for On-Board Cell Lysis

USPTO published patent application US20260098253A1 assigned to Gen-Probe Incorporated. The application covers a lysis vessel for performing cell lysis that includes a laterally extending member and sleeve with dual porous membranes, non-magnetic beads, and at least one magnetic element contained within a lysis chamber. Filing date was December 11, 2025, under application number 19416385.

Circular DNA Purification Using Nanoclays

USPTO published patent application US20260098252A1 by Texas State University (filed October 3, 2025) disclosing a method of purifying circular DNA from samples using nanoclays that preferentially adsorb contaminants including non-circular DNA, RNA, proteins, and endotoxins while leaving circular DNA unbound. The elution-free method separates nanoclay-contaminant complexes from the enriched circular DNA fraction. The invention also covers compositions and systems for such purification and methods of refining nanoclays for the purification process.

Nucleic Acid Extraction Methods, Waters Corp, 9th Apr

Nucleic Acid Extraction Methods, Waters Corp, 9th Apr

UORF Editing to Improve Crop Plant Agronomic Traits

USPTO published patent application US20260098275A1 assigned to Inari Agriculture Technology, Inc., disclosing methods of improving agronomic traits in crop plants through editing sequences within the 5' untranslated region (5' UTR) of plant genomes. The application names Ross Everett Altman, Malachy T. Campbell, Karl Anton Grothe Kremling, and Ruijuan Li as inventors. Filing date was April 10, 2024.

Root-Mediated Uptake of Guide RNA for Genomic Editing of a Plant

USPTO published patent application US20260098274A1 by Inari Agriculture Technology disclosing methods for editing plant genomes by delivering guide RNA to plant roots for CRISPR-Cas editing in meristems. Inventors include Aran McCay, Michael Lee Nuccio, and Palak Kathiria. The filing date was March 7, 2024.

KWS SAAT Immature Inflorescence Meristem Gene Editing

KWS SAAT SE & Co. KGaA has published a patent application (US20260098273A1) for a method of plant genome modification targeting immature inflorescence meristem (IIM) cells. The method uses genome editing systems with optional regeneration boosters, delivered via particle bombardment, to modify genomic target sites in plant cells and regenerate modified plant tissues, organs, or seeds.

DNA Origami Nanostructures for Molecular Data Storage Patent Application

USPTO published patent application US20260098258A1 on April 9, 2026, disclosing compositions and methods using DNA origami principles to package and archive data stored in multiple indexed DNA oligonucleotides. The application (No. 19319178, filed September 4, 2025) covers DNA origami (DNAO) nanostructures enabling selective physical data access and retrieval from a molecular pool.

Protein Evolution System With DNA Synthesis, Microfluidics

The USPTO published patent application US20260098257A1 covering systems, methods, and kits for rapid protein evolution. The application (No. 19271120, filed July 16, 2025) names five inventors and describes a system combining DNA synthesis, microfluidic devices with sequestration pens, and a computing component for iterative protein optimization. The technology enables cell-free protein expression and assay-based evaluation of protein variants.

Methods for Assaying Enriched Nucleic Acids Using Complementary Probes

The USPTO published patent application US20260098304A1 covering methods for assaying enriched nucleic acids using probes with sequences complementary to RNA expression products to determine expression levels of multiple genes. The application was filed on October 3, 2024 by inventors including Charles M. Perou, Joel S. Parker, and others. The claimed methods enable enrichment of nucleic acid molecules for gene expression analysis in biological samples.

Cell-Free PPi-Driven ATP Regeneration Platform Patent

Cell-Free PPi-Driven ATP Regeneration Platform Patent

Modified Double-Stranded RNA Agents Inhibit Gene Expression

USPTO published patent application US20260098263A1 for modified double-stranded RNA (dsRNA) agents capable of inhibiting gene expression. The application was published April 9, 2026, with inventors Martin MAIER, Don FOSTER, Stuart MILSTEIN, Satya KUCHIMANCHI, Vasant JADHAV, Kallanthottathil RAJEEV, Muthiah MANOHARAN, and Rubina PARMAR. The dsRNA agents contain thermally destabilizing nucleotides positioned opposite the seed region of the antisense strand and modified nucleotides with reduced steric bulk, with pharmaceutical compositions and therapeutic methods for treating disease conditions also disclosed.

Methods and Compositions for Designing and Selecting TinyRNAs to Maximize Target Cleavage

USPTO published patent application US20260098266A1 by Kotaro NAKANISHI disclosing methods for designing and selecting tinyRNAs with guide RNA and Argonaute molecules for gene expression regulation in biotherapeutic and diagnostic applications. The application was filed April 1, 2024, and published April 9, 2026.

Exon 44 Duchenne Muscular Dystrophy Cyclic Peptide Antisense

The USPTO published patent application US20260098262A9 covering compositions comprising a cyclic peptide and an antisense compound targeting exon 44 of the DMD gene for Duchenne Muscular Dystrophy treatment. The application was filed on August 30, 2022, under application number 18688083, listing nine inventors including Xiang Li, Ziqing Qian, and others. No compliance obligations or deadlines are associated with this publication. This patent application publication represents a formal administrative record from the USPTO but does not create any regulatory obligations or deadlines for affected parties. Pharmaceutical and biotechnology companies developing exon-skipping therapies for DMD may wish to review the claims for potential freedom-to-operate implications.

Self-Circularized RNA Preparation Method, Apr 09

Self-Circularized RNA Preparation Method, Apr 09

CRISPR/Cpf1 Gene Editing Systems Using Recombinant AsCpf1 and LbCpf1 crRNA

The USPTO published patent application US20260098249A1 for Integrated DNA Technologies covering recombinant AsCpf1 and LbCpf1 nucleic acids and polypeptides for CRISPR/Cpf1 endonuclease gene editing systems in mammalian cell lines. The application includes ribonucleoprotein complexes using length-truncated, chemically-modified, or dual-modified AsCpf1 crRNAs and methods for performing gene editing using these systems.

CRISPR/Cas9 Gene Editing Method for Beta-Amyloid Pathway Attenuation

USPTO published patent application US20260097136A1 filed by Wisconsin Alumni Research Foundation on November 12, 2025. The application covers CRISPR/Cas9 constructs designed for C-terminal truncation of human amyloid precursor protein (APP) to attenuate the beta-amyloid pathway implicated in Alzheimer's disease, along with methods of making and using such constructs. The publication provides public notice of the claimed gene-editing technology and its potential therapeutic applications in neurodegenerative disease. No enforceable rights are granted until a patent issues following examination.

siRNA Molecules Targeting ATXN3 Gene for Spinocerebellar Ataxia Treatment

The USPTO published patent application US20260098265A1 disclosing single- or double-stranded siRNA molecules targeting the ataxin-3 (ATXN3) gene for treatment of spinocerebellar ataxias, including spinocerebellar ataxia type 3. The application includes branched siRNA designs (di-branched, tri-branched, tetra-branched) with nucleoside modifications, 5' phosphorus stabilizing moieties, and methods for CNS delivery. The application was filed on September 28, 2023.

Genentech Modified CHO Cells for Therapeutic Protein Production

USPTO published patent application US20260098254A1 by Genentech, Inc. covering modified CHO cells for therapeutic protein production. The application claims methods, cells, and compositions where mammalian cells have reduced or eliminated activity of host cell proteins including lipases, esterases, and hydrolases. Application No. 19408114 was filed December 3, 2025.

Modified siRNA Targeting C9orf72 Gene for Neurological Disorder Treatment

USPTO published patent application US20260098264A1 for modified single- or double-stranded siRNA molecules targeting the C9orf72 gene for treatment of neurological disorders including amyotrophic lateral sclerosis and frontotemporal dementia. The application covers branched siRNA structures with nucleoside modifications, phosphorus stabilizing moieties, and methods for CNS delivery.

Affinity Chromatography Column for Cell Binding

USPTO published patent application US20260098840A1 by TQ Therapeutics GmbH for a column design for affinity chromatography. The invention comprises a column body with a retention volume containing a stationary phase, open ends for cell addition/removal, and obstacles such as grids or pins. The application covers the column design, a system of columns, and methods for binding cells using the disclosed technology.

Compositions and Methods for Screening Mutations in Thyroid Cancer

The USPTO published patent application US20260098297A1 on April 9, 2026, disclosing methods for screening mutations in thyroid cancer to determine whether patients with indeterminate thyroid nodules should undergo diagnostic surgery. The application covers screening patient thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to thyroid cancer-related genes. Six inventors are named including Shih-Min Cheng, Joseph Catanese, and Andrew Grupe. Filing date was December 9, 2025.

Low Dose Psilocybin in Foodstuff and Microbes for Same

USPTO published patent application US20260098286A1 by ATX PHARMERS LLC covering engineered microbes transformed with psilocybin genes under weak or medium-level promoters to produce low levels of psilocybin, with applications in microdose and sub-microdose foodstuff production. No compliance obligations or deadlines are imposed by this publication.

Cre-Lox AAV Gene Therapy Reconstitution System for Large Gene Delivery

The USPTO published patent application US20260098279A1 for a Cre-Lox AAV gene therapy system enabling delivery of therapeutic genes up to 16kb using up to four adeno-associated virus vectors with sequence-specific recombination. The invention by inventor Seongjin Seo includes novel lox site embodiments for near-unidirectional recombination. Applications include treatment of genetic disorders such as IFT140-associated retinitis pigmentosa and other retinal degeneration conditions.

Cells, Organs with Modified Genes for Xenograft Tolerance

Cells, Organs with Modified Genes for Xenograft Tolerance

Recombinant Yeast with Sucrose-Inducible Promoter for Target Protein Expression

USPTO published patent application US20260098241A1 assigned to FUJIFILM Corporation covering recombinant yeast strains containing sucrose-inducible promoters for highly expressing target proteins without methanol, along with production methods and kits.

Fungal Spore Production Method Using Dual Liquid Medium

The USPTO published patent application US20260098242A1 covering a method for producing fungal spores using a dual liquid medium system. The first medium has a lower carbon content than the second medium. Inventors: Van De Zilver Eric, Laurens Van Leeuwen. Application filed September 26, 2023; published April 9, 2026.

Mammoth Biosciences CRISPR Dystrophin Editing Patent Application

USPTO published patent application US20260097134A1 assigned to Mammoth Biosciences, Inc. covering CRISPR-Cas systems and methods for editing human dystrophin genes to treat Duchenne muscular dystrophy (DMD). The application includes compact Type V CRISPR-associated proteins, RNA-dependent DNA polymerase, and guide nucleic acids for gene modification therapies.

Recombinant AAV Vectors for Treating Muscular Dystrophy

USPTO published patent application US20260097132A1 assigned to Sarepta Therapeutics, Inc. covering recombinant adeno-associated virus (rAAV) vectors for expressing human micro-dystrophin gene to treat muscular dystrophy, including Duchenne Muscular Dystrophy. The application includes methods for genotyping DMD gene to determine rAAV gene therapy contraindications. Filing date was September 22, 2023.